Roivant signals imminent brepocitinib data readout in dermatomyositis while advancing $500M share repurchase Roivant signals imminent brepocitinib data readout in dermatomyositis while advancing $500M share repurchase Post ContentroivRead More You might also be interested in reading Jim Chanos is Buying Bitcoin and Shorting Strategy. August 11, 2025 In Mainstream ← Previous post Next post →